Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 10278 publications.
Skip to main content
Gilsenan A, Shakir S, Jokinen J. Pharmacovigilance: beyond signal detection and spontaneous reporting. Presentation to be given at the DIA 2025 Global Annual Meeting; June 16, 2025. Washington, DC.
Nardoni V, Lippi M, Marinai S, Hyeraci G, Maccari M, Arana A, Lucenteforte E, Limoncella G, Mohammadi S, Roberto G, Dehghan Tarazjani A, Virgili G, Weibel D, Gini R. Comparing humans and large language models in filling clinical questionnaires. Presentation to be given at the 4th International Conference Series on Hybrid Human-Artificial Intelligence; June 9, 2025. Pisa, Italy.
MacDonald SC, Rivero-Ferrer E, Bell EJ, Franklin J, Hardy J, Margulis AV, Seals R, Yang R, Seeger J, Straghan E, Asomaning K. A retrospective cohort database study to evaluate the safety of rimegepant exposure during pregnancy. Poster to be given at the 38th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research; June 9, 2025. Boston, MA.
Korver D. A gentle introduction to creating graphs in Python, R and SAS. Presentation to be given at the PharmaSUG US Conference; June 2, 2025. San Diego, CA.
Shirneshan E, Smith E, Shewale A, Stokes J, Kosa K, DiBenedetti D. Patient and caregiver experiences with ischaemic stroke: results from a qualitative study. Poster presented at the 11th European Stroke Organization Conference (ESOC) 2025; May 21, 2025. Helsinki, Finland.
Bozzi LM, Johnson R, Heidenreich S, Poulos C. Alternative recruitment options for patient preference studies: thinking outside the market research panel box. Presented at the ISPOR 2025; May 16, 2025. Montréal, Canada.
Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster presented at the ISPOR 2025; May 16, 2025. Montréal, Canada.
La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Copley-Merriman K, Doward L, Hawe E, Cope S. Clinical trial design, beyond the regulatory. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Brogan A, Zhang K. From data to dialogue: mastering conversations to amplify HEOR impact and influence. Presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Loria-Rebolledo L, Watson V, Mohan D, Vass CM, Antunes M, Burns D, Ryan M. Over 30 years of discrete choice experiment studies in health economics: systematic review of current practice and reflections on evolving practice. Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Marcano Belisario J, Lunan M, Hawe E, Farrelly G. Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Sauchelli S, Chicklis EK, Carty MK, Gnanasakthy A. Use of diaries to capture patient-reported outcomes in FDA new drug approvals (2019-2023). Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Ronquest N, Zhang Y, Mladsi D. Assessing the impact of the United States (US) Inflation Reduction Act (IRA) regulations on investment incentives for orphan disease drug development. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Paulsen R, (Demuro) Romano C, Frangiosa T, Mordin M, Dardis GJ, DiBenedetti D, Petersen RC, Cummings JL. How do we put meaning into meaningful benefit? Perspectives from the lived experience - Commentary. Alzheimers Dement (NY). 2025 May 14;11(2):e70095. doi: 10.1002/trc2.70095
Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster presented at the ISPOR 2025; May 13, 2025. Montréal, Canada.
Bagnato F, Mordin M, Greene N, Mahida S, van Wingerden J. Associations between chronic active lesions and clinical outcomes in multiple sclerosis: a systematic literature review. J Manag Care Spec Pharm. 2025 May 13;1-28. doi: 10.18553/jmcp.2025.24294
Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ. Advanced patient-reported outcomes. Mastering Patient-Reported Outcomes (PRO) in Drug Development. Presented at the ISPOR 2025; May 13, 2025. Montréal, Canada. Previously presented at the ISPOR Europe 2024.
Layton JB, Lloyd PC, Peetluk LS, Jiao Y, Djibo DA, Gruber JF, Deng J, Bui C, Lo AC, Ogilvie RP, Parambi R, Miller M, Song J, Weatherby LB, Cho S, Wong HL, Clarke TC, Hervol JR, Illei D, Bell EJ, Yang GW, Seeger JD, Wernecke M, Richey MM, Forshee RA, Anderson SA, Chillarige Y, McMahill-Walraven CN, Amend KL, Anthony MS, Shoaibi A. Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States. PLoS One. 2025 May 6;20(5):e0320434. doi: 10.1371/journal.pone.0320434
Dellon ES, Goodwin B, Liu Y, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Healthcare resource utilization and associated costs in patients with eosinophilic esophagitis: a retrospective cohort study of US health insurance claims data. Poster presented at the Digestive Disease Week (DDW) 2025; May 3, 2025. San Diego, CA.
Messina AJ. Commentary - Why the pharmaceutical industry needs implementation science for sustainable innovation. Pharmaceut Med. 2025 May 2. doi: 10.1007/s40290-025-00566-x
Pladevall-Vila M, Ziemiecki R, Johannes CB, Khan AM, Mines D, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Bernal CR, Cabaninas CR, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Beest FJAP, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study. Diabetes Ther. 2025 May;16(5):931-54. doi: 10.1007/s13300-025-01717-8
Hood K, Bensink M, Ayoub I, Peipert JD, Trachtman H, Wadhwani S, Garbinsky D, Wang J, Zhou X, Bennett L, Choi J, Gong W, Inrig JK, Komers R. Patient-reported outcomes in rare kidney disease clinical trials: sparsentan versus irbesartan. Poster presented at the American Nephrology Nurses Association (ANNA) National Symposium; May 1, 2025. Portland, OR.
Francis N, Arends S, Choi JC, Becker B, Edwards T, Sreih A, Christodoulou A, Strand V. Qualitative study on patient-reported outcome measures in patients with Sjögren's disease. Poster presented at the Congress of Clinical Rheumatology - East 2025; May 1, 2025. Destin, FL.
Francis N, Merola JF, Werth V, Choi JC, Becker B, Edwards T, Hobar C, Pomponi S, Strand V. Qualitative patient interview study in patients with systemic lupus erythematosus: patient reports of fatigue and skin-related symptoms. Poster presented at the Congress of Clinical Rheumatology - East 2025; May 1, 2025. Destin, FL.
George S, Carrico J, Hicks KA, Loukov D, Ng C, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada. BMC Health Serv Res. 2025 Apr 25;25(1):604. doi: 10.1186/s12913-025-12550-x
Broughton E, Bektas M, Colosia A, Kuper K, Fernandez MM, Al-Taie A, Kotb R. A systematic literature review of the epidemiology of complicated urinary tract infection. Infect Dis Ther. 2025 Apr 24. doi: 10.1007/s40121-025-01149-8
Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices. Hum Vaccin Immunother. 2025 Apr 18;21(1):2488093. doi: 10.1080/21645515.2025.2488093
Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762
Leber B, Ruiz MT, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh AC. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer. 2025 Apr 15;131(8):e35845. doi: 10.1002/cncr.35845
Sauchelli S, Levy C, Gnanasakthy A, Dave V, Doward L, Fitzgerald KA, Carson R. From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018-2022). Front Pharmacol. 2025 Apr 11;16:1536401. doi: 10.3389/fphar.2025.1536401
Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8
La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057
Custer N, Lesko T, Reategui EP. What is data integrity and data quality? In: Richard M Siconolfi, Catherine Bens, Josepah A. Franchetti, Cheryl M. McCarthy, editors. Data integrity: the science, the regulations, the use. First ed. Charlottesville: VA. SQA Learning Foundation Educational Book; 2025.
Abbatemarco J, Yu J, Kleman M, Myers K, Poulos C, Conway D. Patient preferences for treatment features in Neuromyelitis Optica Spectrum Disorder (NMOSD): results from a discrete choice experiment (DCE). Poster presented at the American Academy of Neurology 2025 Annual Meeting; April 5, 2025. San Diego, CA. [abstract] Neurology. 2025 Apr 8; 104(7_Suppl 1):7-8.013. doi: 10.1212/WNL.0000000000208724
La EM, Sweeney C, Davenport E, Calhoun S, Harmelink A, Singer D. Healthcare professionals' knowledge, attitudes, and practices regarding respiratory syncytial virus disease and vaccination in adults aged 60 years and older. Infect Dis Ther. 2025 Apr;14(4):735-52. doi: 10.1007/s40121-025-01119-0
Poulos C, Marcek T, Chintakayala P, Boeri M, Francis A, Langevin E, Petigara T, O'Connor J, Samant S. Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):543-50. doi: 10.1080/14737167.2025.2450352
Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE, Riedl MA, Vanegas A, Boyle K, Bartsch JL, Darden C, Brown TM, Schultz BG, Blair C, Sing K, Fox D, Juethner S. Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. 2025 Apr;134(4):465-473.e. doi: 10.1016/j.anai.2025.01.007